Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial

This article was originally published in PharmAsia News

Executive Summary

TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12
Advertisement

Related Content

Millennium Poised To Deliver Late-Stage Pipeline: Q&A With Dr. Karen Ferrante
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Takeda Readying To Launch PPI Kapidex Within A Month
Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
Takeda Expands Antibody Collaboration With Xoma
Takeda Expands Antibody Collaboration With Xoma
Advertisement
UsernamePublicRestriction

Register

SC070760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel